Malignant gastroenteropancreatic neuroendocrine tumor

A malignant gastroenteropancreatic neuroendocrine tumor is a cancerous neoplasm arising from the diffuse neuroendocrine cell system of the digestive tract or the endocrine pancreas Clinically, they can be classified as nonfunctional, presenting late with mass-effect symptoms such as abdominal pain, bleeding, or obstruction, or functional, presenting with hypersecretory syndromes—such as carcinoid syndrome, refractory peptic ulcer disease, or hypoglycemia—driven by excess secretion of biologicall...

A malignant gastroenteropancreatic neuroendocrine tumor is a cancerous neoplasm arising from the diffuse neuroendocrine cell system of the digestive tract or the endocrine pancreas Pathophysiologically, these tumors originate primarily in the stomach, intestines, rectum, or pancreatic islets, exhibiting features of local tissue invasion and metastatic potential, most frequently to regional lymph nodes and the liver

A malignant gastroenteropancreatic neuroendocrine tumor is a cancerous neoplasm arising from the diffuse neuroendocrine cell system of the digestive tract or the endocrine pancreas

Pathophysiologically, these tumors originate primarily in the stomach, intestines, rectum, or pancreatic islets, exhibiting features of local tissue invasion and metastatic potential, most frequently to regional lymph nodes and the liver Clinically, they can be classified as nonfunctional, presenting late with mass-effect symptoms such as abdominal pain, bleeding, or obstruction, or functional, presenting with hypersecretory syndromes—such as carcinoid syndrome, refractory peptic ulcer disease, ...

Pathophysiologically, these tumors originate primarily in the stomach, intestines, rectum, or pancreatic islets, exhibiting features of local tissue invasion and metastatic potential, most frequently to regional lymph nodes and the liver

Clinically, they can be classified as nonfunctional, presenting late with mass-effect symptoms such as abdominal pain, bleeding, or obstruction, or functional, presenting with hypersecretory syndromes—such as carcinoid syndrome, refractory peptic ulcer disease, or hypoglycemia—driven by excess secretion of biologically active amines and peptide hormones

Clinically, they can be classified as nonfunctional, presenting late with mass-effect symptoms such as abdominal pain, bleeding, or obstruction, or functional, presenting with hypersecretory syndromes—such as carcinoid syndrome, refractory peptic ulcer disease, or hypoglycemia—driven by excess secretion of biologically active amines and peptide hormones